Research
Hormonal
Semaglutide (GLP-1 receptor agonist) produces significant weight loss (15.5% in adolescents, 12.5% in adults) and cardiovascular benefits, making it a prioritized treatment for those with metabolic risk factors.
Semaglutide is a highly effective weekly injection that can lead to significant weight loss (12-15%) and cardiovascular benefits. It is particularly recommended for those with metabolic risks or low satiety.
GoodSupportsHIGH confidence
Semaglutide has demonstrated a 15.5%-weight loss in adolescents and a 12.5%-weight reduction in adults after 68 weeks of treatment [27, 28].
Why this rating
Based on clinical trials cited in the review; robust data for adults and adolescents.
Source
Obesity treatment in adolescents and adults in the era of personalized medicine
Magnus Sundbom et al. · Journal of Internal Medicine · 2024
DOI 10.1111/joim.13816
narrative_reviewCited 13×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Lifestyle treatment alone has modest or little long-term effect on weight loss, particularly in adults, and is often insufficient for sustainable weight maintenance due to biological drivers like hunger.Strong
- Gastric bypass results in large and long-lasting weight loss (25-27% total body weight loss at 12-15 years) and remission of obesity-related conditions, making it suitable for patients with BMI 35-50 kg/m2, especially with type 2 diabetes or reflux.Good
- Phenotype-guided pharmacotherapy (matching 'hungry gut' to GLP-1, 'hungry brain' to phentermine-topiramate, and 'slow burn' to phentermine + resistance training) yields 1.75-fold greater weight loss compared to non-phenotype-guided treatment.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →